Which has stronger valuation & earnings, ACIU or CRON?

Cronos Group has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AC Immune $3.70M 71.07 -$85.03M -$0.82 N/A Cronos Group $146.59M 7.11 -$9.45M $0.01 279.50

Is ACIU or CRON more profitable?

Cronos Group has a net margin of -1.14% compared to AC Immune's net margin of -1,788.02%. Cronos Group's return on equity of -1.26% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% Cronos Group -1.14% -1.26% -1.20%

Which has higher valuation & earnings, BIOA or ACIU?

BioAge Labs has higher revenue and earnings than AC Immune. BioAge Labs is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAge Labs $10.32M 104.93 -$80.61M -$2.40 N/A AC Immune $3.70M 71.07 -$85.03M -$0.82 N/A

Is BIOA or ACIU more profitable?

BioAge Labs has a net margin of -871.75% compared to AC Immune's net margin of -1,788.02%. BioAge Labs' return on equity of -29.40% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets BioAge Labs -871.75% -29.40% -27.26% AC Immune -1,788.02% -125.26% -40.85%

Is ACIU or REPL more profitable?

Replimune Group has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Replimune Group's return on equity of -102.69% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -1,788.02% -125.26% -40.85% Replimune Group N/A -102.69% -72.22%

Is DBVT or ACIU more profitable?

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -2,895.37%. AC Immune's return on equity of -125.26% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -2,895.37% -129.88% -88.84% AC Immune -1,788.02% -125.26% -40.85%

AC Immune (ACIU) Competitors

$2.58 +0.03 (+0.98%)

As of 10:51 AM Eastern

Compare

ACIU vs. CRON, BIOA, REPL, AVTX, and DBVT

Should you buy AC Immune stock or one of its competitors? MarketBeat compares AC Immune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AC Immune include Cronos Group (CRON), BioAge Labs (BIOA), Replimune Group (REPL), Avalo Therapeutics (AVTX), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.

How does AC Immune compare to Cronos Group?

AC Immune (NASDAQ:ACIU) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

AC Immune currently has a consensus price target of $7.50, indicating a potential upside of 190.14%. Cronos Group has a consensus price target of $2.30, indicating a potential downside of 17.71%. Given AC Immune's stronger consensus rating and higher possible upside, equities analysts clearly believe AC Immune is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

AC Immune has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

Cronos Group has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$3.70M	71.07	-$85.03M	-$0.82	N/A
Cronos Group	$146.59M	7.11	-$9.45M	$0.01	279.50

In the previous week, Cronos Group had 3 more articles in the media than AC Immune. MarketBeat recorded 4 mentions for Cronos Group and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat Cronos Group's score of 0.91 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Very Positive
Cronos Group	Positive

Cronos Group has a net margin of -1.14% compared to AC Immune's net margin of -1,788.02%. Cronos Group's return on equity of -1.26% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Cronos Group	-1.14%	-1.26%	-1.20%

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 7.8% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cronos Group beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does AC Immune compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and AC Immune (NASDAQ:ACIU) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

BioAge Labs has a net margin of -871.75% compared to AC Immune's net margin of -1,788.02%. BioAge Labs' return on equity of -29.40% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
AC Immune	-1,788.02%	-125.26%	-40.85%

BioAge Labs has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

BioAge Labs currently has a consensus target price of $43.50, indicating a potential upside of 78.64%. AC Immune has a consensus target price of $7.50, indicating a potential upside of 190.14%. Given AC Immune's higher probable upside, analysts clearly believe AC Immune is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

51.4% of AC Immune shares are held by institutional investors. 20.8% of BioAge Labs shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioAge Labs has higher revenue and earnings than AC Immune. BioAge Labs is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$10.32M	104.93	-$80.61M	-$2.40	N/A
AC Immune	$3.70M	71.07	-$85.03M	-$0.82	N/A

In the previous week, BioAge Labs had 4 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for BioAge Labs and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat BioAge Labs' score of 0.47 indicating that AC Immune is being referred to more favorably in the news media.

Company	Overall Sentiment
BioAge Labs	Neutral
AC Immune	Very Positive

Summary

BioAge Labs beats AC Immune on 10 of the 16 factors compared between the two stocks.

How does AC Immune compare to Replimune Group?

AC Immune (NASDAQ:ACIU) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

51.4% of AC Immune shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 5.2% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Replimune Group has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Replimune Group's return on equity of -102.69% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Replimune Group	N/A	-102.69%	-72.22%

AC Immune has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$3.70M	71.07	-$85.03M	-$0.82	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

AC Immune has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, Replimune Group had 6 more articles in the media than AC Immune. MarketBeat recorded 7 mentions for Replimune Group and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat Replimune Group's score of 1.28 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Very Positive
Replimune Group	Positive

AC Immune presently has a consensus price target of $7.50, suggesting a potential upside of 190.14%. Replimune Group has a consensus price target of $6.00, suggesting a potential downside of 46.73%. Given AC Immune's stronger consensus rating and higher probable upside, analysts plainly believe AC Immune is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Replimune Group	3 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

AC Immune beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does AC Immune compare to Avalo Therapeutics?

AC Immune (NASDAQ:ACIU) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Avalo Therapeutics has lower revenue, but higher earnings than AC Immune. Avalo Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$3.70M	71.07	-$85.03M	-$0.82	N/A
Avalo Therapeutics	$60K	16,542.03	-$78.26M	-$5.46	N/A

AC Immune currently has a consensus target price of $7.50, suggesting a potential upside of 190.14%. Avalo Therapeutics has a consensus target price of $46.67, suggesting a potential upside of 147.18%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, Avalo Therapeutics had 6 more articles in the media than AC Immune. MarketBeat recorded 7 mentions for Avalo Therapeutics and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat Avalo Therapeutics' score of 0.65 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Very Positive
Avalo Therapeutics	Positive

Avalo Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Avalo Therapeutics' return on equity of -97.54% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
Avalo Therapeutics	N/A	-97.54%	-72.42%

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AC Immune has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Summary

AC Immune and Avalo Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does AC Immune compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

DBV Technologies has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

DBV Technologies currently has a consensus target price of $48.50, suggesting a potential upside of 193.07%. AC Immune has a consensus target price of $7.50, suggesting a potential upside of 190.14%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, DBV Technologies had 2 more articles in the media than AC Immune. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for AC Immune. AC Immune's average media sentiment score of 1.89 beat DBV Technologies' score of 0.63 indicating that AC Immune is being referred to more favorably in the news media.

Company	Overall Sentiment
DBV Technologies	Positive
AC Immune	Very Positive

AC Immune has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A
AC Immune	$3.70M	71.07	-$85.03M	-$0.82	N/A

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AC Immune has a net margin of -1,788.02% compared to DBV Technologies' net margin of -2,895.37%. AC Immune's return on equity of -125.26% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
AC Immune	-1,788.02%	-125.26%	-40.85%

Summary

AC Immune beats DBV Technologies on 10 of the 16 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$262.98M	$3.63B	$6.84B	$12.34B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-3.15	21.47	25.87	24.19
Price / Sales	71.07	340.70	553.99	100.49
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	4.79	8.38	10.79	6.42
Net Income	-$85.03M	$23.92M	$3.58B	$337.00M
7 Day Performance	3.40%	2.52%	2.49%	0.94%
1 Month Performance	-2.82%	0.15%	0.21%	-0.66%
1 Year Performance	28.61%	66.07%	35.20%	27.96%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	2.8334 of 5 stars	$2.59 +1.0%	$7.50 +190.1%	+26.6%	$262.98M	$3.70M	N/A	140	Positive News
CRON Cronos Group	1.38 of 5 stars	$2.69 +1.3%	$2.30 -14.3%	+47.9%	$1.00B	$146.59M	268.77	450
BIOA BioAge Labs	2.5745 of 5 stars	$22.40 +4.3%	$43.50 +94.2%	N/A	$995.97M	$10.32M	N/A	N/A	Gap Down
REPL Replimune Group	1.9725 of 5 stars	$11.93 +6.7%	$4.88 -59.2%	+24.7%	$990.88M	N/A	N/A	210	Positive News Earnings Report Analyst Upgrade
AVTX Avalo Therapeutics	3.399 of 5 stars	$18.23 +6.7%	$46.67 +156.0%	+280.0%	$960.72M	$60K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors

ACIU vs. CRON, BIOA, REPL, AVTX, and DBVT

How does AC Immune compare to Cronos Group?

Summary

How does AC Immune compare to BioAge Labs?

Summary

How does AC Immune compare to Replimune Group?

Summary

How does AC Immune compare to Avalo Therapeutics?

Summary

How does AC Immune compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AC Immune (ACIU) Competitors

ACIU vs. CRON, BIOA, REPL, AVTX, and DBVT

How does AC Immune compare to Cronos Group?

Do analysts prefer ACIU or CRON?

Which has more volatility and risk, ACIU or CRON?

Which has stronger valuation & earnings, ACIU or CRON?

Does the media favor ACIU or CRON?

Is ACIU or CRON more profitable?

Do insiders and institutionals believe in ACIU or CRON?

Summary

How does AC Immune compare to BioAge Labs?

Is BIOA or ACIU more profitable?

Which has more volatility and risk, BIOA or ACIU?

Do analysts recommend BIOA or ACIU?

Do institutionals & insiders believe in BIOA or ACIU?

Which has higher valuation & earnings, BIOA or ACIU?

Does the media refer more to BIOA or ACIU?

Summary

How does AC Immune compare to Replimune Group?

Do institutionals and insiders hold more shares of ACIU or REPL?

Is ACIU or REPL more profitable?

Which has better valuation and earnings, ACIU or REPL?

Which has more risk and volatility, ACIU or REPL?

Does the media prefer ACIU or REPL?

Do analysts prefer ACIU or REPL?

Summary

How does AC Immune compare to Avalo Therapeutics?

Which has better earnings and valuation, ACIU or AVTX?

Do analysts recommend ACIU or AVTX?

Does the media refer more to ACIU or AVTX?

Is ACIU or AVTX more profitable?

Do institutionals & insiders hold more shares of ACIU or AVTX?

Which has more risk and volatility, ACIU or AVTX?

Summary

How does AC Immune compare to DBV Technologies?

Which has more risk and volatility, DBVT or ACIU?

Do analysts rate DBVT or ACIU?

Does the media refer more to DBVT or ACIU?

Which has better earnings & valuation, DBVT or ACIU?

Do institutionals and insiders have more ownership in DBVT or ACIU?

Is DBVT or ACIU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools